|ECR 2019 / C-2003|
|Radiomic evaluation of treatment response in patients with glioblastoma: a preliminary study|
Methods and materials
We retrospectively analysed 20 MRI studies of patients with biopsy-proven glioblastoma who had standard chemo-radiotherapy treatment and early progressive enhancing disease. Studies were labelled as true progression (n=11) if there was progression or death within six months or pseudoprogression (n=9) if there was no further progression within six months.
The T1-weighted post-contrast and T2-weighted sequences were co-registered to allow segmentation of tumour components. Enhancing disease and perilesional oedema were segmented from the two sequences respectively to create volumes of interest (Fig. 2) using ITK-SNAP open-source software4 with a semi-automatic method with manual adjustment.
References: - Birmingham/UK
Radiomic texture features were extracted from the volumes of interest using CaPTk software5 and more than 280 features were extracted per MRI sequence. The features included morphological, grey level co-occurrence matrix (GLCM), grey level run length matrix (GLRLM), neighbouring grey tone difference matrix (NGTDM) and grey level size-zone matrix (GLSZM) features. Statistical analysis was performed using SPSS software to calculate the differences between the true progression and pseudoprogression groups.
Thematically related posters
ECR 2019 / C-3246
Precision Radiology in Glioma Prognostication: Machine Learning & Quantifiable Biomarkers